1. Incidence of symptomatic Lyme borreliosis in nine European countries.
- Author
-
Angulo FJ, Colby E, Lebech AM, Lindgren PE, Moniuszko-Malinowska A, Strle F, Olsen J, Brestrich G, Vyse A, Shafquat M, Gould LH, Kelly PH, Pilz A, Halsby K, Moïsi JC, and Stark JH
- Subjects
- Humans, Incidence, Europe epidemiology, Seroepidemiologic Studies, Antibodies, Bacterial blood, Borrelia burgdorferi Group isolation & purification, Prevalence, Male, Female, Adult, Lyme Disease epidemiology, Lyme Disease diagnosis
- Abstract
Objectives: To better understand the Lyme borreliosis (LB) burden in Europe, we aimed to estimate the incidence of symptomatic Borrelia burgdorferi sensu lato (Bbsl) infections after adjusting public health LB surveillance data for under-detection of symptomatic Bbsl infections., Methods: Data from seroprevalence studies and estimates of the symptomatic proportion and duration of antibody detection in Bbsl-infected individuals, derived from reviews of the published literature, were used to adjust public health LB surveillance data to estimate the incidence of symptomatic Bbsl infection in nine European countries from 2018 to 2022., Results: The prevalence of anti-Bbsl antibodies ranged from 2.3% in Romania to 9.4% in Germany. Under-detection multipliers varied across surveillance systems; using 10-year duration of antibody detection, multipliers were 2.4-10.5 in countries reporting all LB cases and 54.6-722.2 in countries reporting only Lyme neuroborreliosis cases. The incidence of symptomatic Bbsl infection adjusted for under-detection was highest in Finland, Germany, Norway, Poland, and Switzerland, intermediate in the Czech Republic and Denmark, and lowest in Ireland and Romania., Conclusion: Adjustment of LB surveillance for under-detection found a high incidence of symptomatic Bbsl infection in several European countries. Differences in LB surveillance systems should be considered when comparing surveillance data between countries and when estimating LB disease burden., Competing Interests: Declarations of competing interest Frederick J. Angulo, Gordon Brestrich, Emily Colby, Andrew Vyse, L. Hannah Gould, Kate Halsby, Patrick H. Kelly, Jennifer C. Moïsi, Andreas Pilz, Madiha Shafquat, and James H. Stark are employees of Pfizer and may hold stock or stock options. Per-Eric Lindgren has been an external scientific advisor to Valneva, Pfizer, and Bavarian-Nordic A/S., (Copyright © 2024 Pfizer Inc. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF